TSE:MDP FY2026 EPS Forecast Increased by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Leede Financial lifted their FY2026 earnings estimates for Medexus Pharmaceuticals in a research note issued on Wednesday, January 22nd. Leede Financial analyst D. Loe now expects that the company will earn $0.29 per share for the year, up from their previous forecast of $0.22. Leede Financial has a "Strong-Buy" rating on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.

MDP has been the topic of a number of other reports. Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 17th. Raymond James upgraded shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price target for the company in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lifted their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. One investment analyst has rated the stock with a buy rating and five have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and an average target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

Shares of MDP traded up C$0.48 during mid-day trading on Friday, reaching C$4.95. The company had a trading volume of 248,718 shares, compared to its average volume of 144,946. The company has a market capitalization of C$121.42 million, a price-to-earnings ratio of 99.00 and a beta of 1.96. The company's 50 day simple moving average is C$3.14 and its 200 day simple moving average is C$2.69. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.